Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | CA12 | O43570 | 4/20 | 0.52 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | CA7 | P43166 | 4/20 | 0.52 |
| ▸ | CA9 | Q16790 | 4/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 3/20 | 0.46 |
| ▸ | DBH | P09172 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | BLM | P54132 | 3/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10830984 | 0.85 | GRM1 (0.41) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL10830071 | 0.77 | CA12 (0.53) | KDM4ECA12CA1CA2CA9 | |
| SCHEMBL14478186 | 0.76 | KDM4E (0.50) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL14640234 | 0.75 | KDM4E (0.42) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL5328242 | 0.75 | TSHR (0.44) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL10830478 | 0.75 | KDM4E (0.47) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL11162284 | 0.73 | CA12 (0.57) | CA12CA1CA2CA7CA9 | |
| Protocatechuic Acid SCHEMBL3985068 | 0.72 | CA12 (0.95) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL7096163 | 0.71 | CA12 (0.61) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL29503047 | 0.71 | CA12 (0.61) | KDM4ECA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0066518-B1 | COMPOUNDS AND METHODS FOR TREATING DEPRESSION | MERRELL DOW FRANCE ET CIE (FR) | 1986-06-11 | — | — | EP | claimed |
| US-4413012-A | Method for treating depression | MERRELL TORAUDE ET COMPAGNIE (FR) | 1983-11-01 | — | — | US | claimed |
| EP-0025233-B1 | METHOD FOR PURIFICATION OF 6-(D-2-(D-2-AMINO-3-N-METHYLCARBAMOYLPROPIONAMIDO)-2-P-HYDROXYPHENYLACETAMIDO)-PENICILLANIC ACID | Tanabe Seiyaku Co., Ltd. (JP) | 1983-03-30 | — | — | EP | claimed |
| EP-0066518-A2 | Compounds and methods for treating depression | MERRELL DOW FRANCE ET CIE (FR) | 1982-12-08 | — | — | EP | claimed |
| US-4346110-A | Method for treating depression | MERRELL TORAUDE ET COMPAGNIE (FR) | 1982-08-24 | — | — | US | claimed |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | SEATTLE GENETICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8343928-B2 | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus | SEATTLE GENETICS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343928-B2 | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus | SEATTLE GENETICS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| EP-0066518-B1 | COMPOUNDS AND METHODS FOR TREATING DEPRESSION | MERRELL DOW FRANCE ET CIE (FR) | 1986-06-11 | — | — | EP | disclosed |
| US-4413012-A | Method for treating depression | MERRELL TORAUDE ET COMPAGNIE (FR) | 1983-11-01 | — | — | US | disclosed |
| US-4413012-A | Method for treating depression | MERRELL TORAUDE ET COMPAGNIE (FR) | 1983-11-01 | — | — | US | disclosed |
| EP-0066518-A2 | Compounds and methods for treating depression | MERRELL DOW FRANCE ET CIE (FR) | 1982-12-08 | — | — | EP | disclosed |
| US-4346110-A | Method for treating depression | MERRELL TORAUDE ET COMPAGNIE (FR) | 1982-08-24 | — | — | US | disclosed |
| US-4346110-A | Method for treating depression | MERRELL TORAUDE ET COMPAGNIE (FR) | 1982-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | KDM4E 648/4885CA12 1610/4885CA1 2482/4885 |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | MMAB, DNPEP, MARCKS | KDM4E 729/4885CA12 1527/4885CA1 2340/4885 |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | PTMS, MMAB, DNPEP | KDM4E 608/4885CA12 1551/4885CA1 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.